Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting PALETTE, an adaptive platform trial studying personalized treatment for sepsis in patients of all ages. The trial focuses on treatable traits identified by biological markers and phenotypes to guide therapy. This flexible design allows simultaneous testing of multiple interventions and rapid inclusion of new treatments, especially useful during pandemics. It aims to improve on standard sepsis trial limitations, which are typically costly and slow. The study evaluates various treatments targeting different sepsis-related traits, such as hyperinflammation, hypoinflammation, macrophage activation syndrome, corticosteroid response, hypercoagulation, and hypofibrinolysis. Treatments include drugs like Tocilizumab, Baricitinib, Anakinra, Hydrocortisone, Heparin, and others, given by oral, subcutaneous, or intravenous routes. Some interventions involve blood purification procedures. Each treatment is administered for a specified period or until hospital discharge or ICU discharge, depending on the intervention. Participants will be monitored for outcomes including all-cause mortality and days alive without life-support therapies at 28 days. Secondary measures include survival up to 3 years, quality of life assessments, incidence of new sepsis episodes, hospitalizations, adverse events, and recovery milestones. The study collects extensive clinical, laboratory, and biomarker data to evaluate treatment effects. The trial plans long-term follow-up up to 3 years to assess safety and health outcomes.
Actively Recruiting
Researchers are evaluating different antimicrobial therapies for infections caused by difficult-to-treat Pseudomonas aeruginosa, a type of bacteria resistant to many common antibiotics. This study focuses on comparing new beta-lactambeta-lactamase inhibitor combinations, cefiderocol, and older treatments like aminoglycosides and colistin to understand their effectiveness in real-life settings for patients facing these challenging infections. The study is a prospective, multicenter cohort involving patients who require intravenous antibiotic treatment for their P. aeruginosa infections. Participating patients will receive one of the available antimicrobial options, and their bacterial samples will be analyzed centrally to assess susceptibility and resistance mechanisms. The study collects clinical data throughout treatment and monitors outcomes such as cure rates, resistance development, adverse events, and mortality. Participants will be followed until hospital discharge and up to 28 days after treatment completion. Researchers will track clinical cures, microbiological eradication, adverse events, emergence of resistance, and acquisition of other multidrug-resistant bacteria. Data collection includes electronic case reports and laboratory testing on bacterial isolates. The total participation duration varies according to hospital stay and follow-up schedules, with rigorous monitoring of safety and treatment outcomes.
Actively Recruiting
Major depressive disorder is a leading cause of disability worldwide, with current treatments like antidepressants often taking 2 to 6 weeks to show effects. This delay can lead to hospitalization for severe major depressive episodes MDE. Researchers are evaluating the early effects of intravenous ketamine, alongside standard venlafaxine treatment, in patients hospitalized with severe unipolar depression to potentially improve early treatment response and reduce risks such as suicidal ideation and long hospital stays. Participants in this study will receive either three doses of intravenous ketamine or placebo on days 1, 4, and 7, in addition to their usual venlafaxine treatment. The study compares ketamine to placebo as an add-on therapy to venlafaxine during this early treatment phase. The study is randomized and quadruple-blinded to assess the efficacy and safety of ketamine in this setting. During the study, participants will be closely monitored for depressive symptoms using tools like the Hamilton Depression Rating Scale HDRS, Beck Depression Inventory BDI, and Clinical Global Impression CGI at multiple time points up to 42 days. Safety parameters such as blood pressure, heart rate, respiratory rate, and side effects like nausea and dissociation will also be tracked. Additional assessments include hospitalization duration, suicidal ideation, anxiolytic use, biomarkers, and PET imaging in a subset of patients. The total follow-up period extends to 42 days after treatment initiation.
Actively Recruiting
Researchers are evaluating whether a personalized rehabilitation program that combines nutrition, physiotherapy, and physical activity, started early in the intensive care unit ICU and continued through hospital discharge and at home, can improve long-term outcomes for patients who have undergone invasive mechanical ventilation and vasopressor therapy. This trial compares this early extended rehabilitation approach to usual care, which involves standard nutritional support and physiotherapy provided according to local ICU practices. Participants will be randomly assigned to either the individualized rehabilitation group or the usual care group. The rehabilitation group will receive a tailored program involving dieticians, physiotherapists, and physical activity instructors, with the intervention continuing for 12 weeks from ICU admission through post-ICU wards and at home. The usual care group will receive standard nutritional and physiotherapy support from day 0 to day 180. Throughout the study, participants will undergo various assessments including physical activity levels, muscle strength, muscle mass, body weight, and quality of life measured at multiple time points up to 12 months after randomization. The primary outcome is the distance walked in six minutes at 6 months. Researchers will also track mortality rates, glucose control, insulin usage, infection rates, and hospital stay lengths. The total participation may last up to 12 months with follow-up evaluations during this period.
Actively Recruiting
People with mental disorders tend to smoke more than the general population, which contributes to a significant reduction in their life expectancy, mainly due to cardiovascular and respiratory diseases like bronchial cancers. Smoking cessation efforts targeting this group, especially in psychiatric care, are often insufficient. This study evaluates a new intervention called Tabapsy, designed in collaboration with mental health users, professionals, and general practitioners, aimed at helping adults receiving outpatient psychiatric care reduce or quit smoking. The Tabapsy intervention includes a campaign promoting smoking cessation within psychiatric medical psychological centers CMPs and a structured program to support quitting. This program involves a general information meeting to encourage motivation, an assessment workshop to personalize cessation plans based on nicotine dependence, five thematic workshops addressing treatments, emotional management, weight gain, physical activities, and manual occupations, plus peer support groups to foster mutual aid. A facilitator leads these workshops, and a website complements the resources provided. The trial compares this intervention against usual smoking cessation practices in randomized psychiatric sectors. Participants who regularly smoke and agree to join will complete questionnaires at the start, 3 months, and 6 months, assessing tobacco use, dependence, motivation, well-being, knowledge, and satisfaction. The study will measure short-term smoking cessation at 3 months as the primary outcome, along with various secondary outcomes including motivation, quit attempts, mental and physical well-being, cost-effectiveness, and implementation success. The trial plans to include 6,250 participants over 12 months and will combine quantitative and qualitative evaluations.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
Researchers are evaluating a new anti-regurgitation infant formula to see how well it reduces regurgitation episodes and improves digestive tolerance in infants with gastroesophageal reflux. This is a randomized, controlled, double-blind trial comparing the new formula to a standard thickened formula. The study is sponsored by United Pharmaceuticals and focuses on infants between 2 weeks and 4 months old. The study includes two groups one receiving the new formula thickened with fibers and the other receiving a formula thickened with locust bean gum. The trial lasts for 1 month and 2 days, starting with a 2-day pre-selection period followed by a 30-day follow-up. Participants can optionally continue for an additional 2 months of follow-up from day 30 to day 90. During the study, infants will be monitored for the frequency and severity of regurgitations, digestive symptoms like diarrhea and constipation, feeding behaviors, sleep quality, and growth measurements including weight, length, head circumference, and BMI. Parents and investigators satisfaction will also be recorded. These assessments occur at days 14, 30, and 90. The primary outcome is the frequency of regurgitation at day 14. All study visits and evaluations are conducted under careful monitoring to track safety and treatment effects.
Actively Recruiting
Researchers are evaluating the French version of the Prediction of Alcohol Withdrawal Severity Scale PAWSS in adults with Alcohol Use Disorders AUD. This observational study aims to validate whether the French version has similar psychometric properties to the original English scale. The PAWSS helps predict the risk of complicated alcohol withdrawal, such as seizures or delirium tremens, which can occur during hospital stays when alcohol consumption stops abruptly. Participants are hospitalized adults aged 18 to 60 with moderate to severe AUD who understand French and are affiliated with the social security system. Participants are followed for three days during their hospital stay. On the first day, they provide consent and clinical data, complete surveys including DSM-5 AUD criteria, AUDIT, the French PAWSS twice by two investigators, and the CIWA-AR scale every 8 hours. On days two and three, the CIWA-AR scale is administered every 8 hours to monitor withdrawal symptoms. During the study, participants complete several questionnaires and scales to assess alcohol withdrawal severity and risk. Researchers measure the psychometric qualities of the French PAWSS and its ability to predict complicated withdrawal, determine the optimal cutoff score, and evaluate benzodiazepine use. The study includes close monitoring of withdrawal symptoms with regular assessments over three days. Participation involves hospital stay assessments and completion of validated scales to support safer withdrawal management.